Download the Whitepaper Now
| This week's Fierce Biotech is brought to you by TD2.
Trouble viewing? Click here. |
| Clinical Detecting Efficacy Early in
Oncology Trials |
|
|
| Early detection of clinical benefit in patients receiving new cancer medicines allows for the rapid recruitment and refinement of clinical trial participants who demonstrate the strongest responses.
Leveraging the best available science focuses on patients most likely to benefit from new medicines. Phase I oncology trials are now efficacy studies and recruitment of potentially target-sensitive patients using advanced analytics, and the early detection of clinical response, allows companies to potentially move from escalation to efficacy determination in as little as 16 months. |
| | |
|
| | Key Success Factors Access to the right patients at the right time drives early, effective results producing evidence that a medicine is providing patient benefit. The use of advanced analytics and real-time data exchange between clinical trial sites and CROs, offers patients access to best available treatments and puts the most promising medicines on a swift path to approval. |
| | |
|
| |
| Free White Paper: Detecting Efficacy Early in Oncology Trials The innovations that have emerged in detecting early activity of new cancer medicines provides patients accelerated access to new drugs designed to treat their cancer. Our free white paper outlines the key success factors in moving a drug forward and getting it to patients who need it the most.
| |
|
| |
| | | Contact Us Ready to get started? If you’re seeking an oncology-focused partner with a strong track record for clinical trial design and an innovative approach, we can help.
Our expert team can help advance your oncology drug development strategy with innovation and efficiency, utilizing the latest technologies and deep oncology experience to manage your trial from beginning to end. With an eye on efficacy at all times and expedited access to the right patients and technologies, TD2 can accelerate your timeline while providing knowledgeable resources and insights every step of the way. Contact us to get started today.
|
| | |
|
| Unmatched Scientific Expertise | Accelerated Development | Committed to Your Goals | Patient-Centered |
|
|
| Want to reach 137,000+ Fierce Biotech subscribers with your own message?
Contact aalcover@questex.com or call 202-824-5074.
You are currently subscribed as newsletter@newslettercollector.com.
If you no longer wish to receive communications from Fierce Biotech's trusted partners, simply click here to unsubscribe.
Refer to our Privacy Policy.
Questex, LLC
685 3rd Avenue, 21st Floor
New York, NY 10017 |
